This program project application represents an integrated and focused multi-disciplinary approach to molecular profiling of colon cancer for improved individualized treatment of this disease. Over 50,000 patients die each year in the United Sates of uncontrolled metastatic colon cancer. Despite extensive morphological and molecular information, it is presently impossible to predict outcome accurately for individual patients, or to calibrate therapy to the molecular state of the tumor. Thus, there is an urgent need to discover reliable molecular markers or targets for the diagnosis, prognosis, and treatment of cancer. For the better part of a century physicians have relied on histological and clinical criteria for developing prognosis. Unfortunately, while these criteria predict average outcomes, tumor variability prevents meaningful individual prediction and decisions. Preliminary expression profiling of solid tumors using SAGE, cDNA, and oligonucleotide arrays has yielded volumes of data, yet variation between tumors has yielded little concordance among the different techniques, nor accurate predictors of outcome. The current program project application is distinguished from previous approaches by: (i) determining the genetic and epigenetic profiles, (ii) determining mRNA profiles on the same human tumor sample, and (iii) using biostatistic, clustering and neural net analysis to guide gene prioritization and outcome analysis. Our strategic approach is to: (i) Develop and validate colon-specific cDNA arrays, our ligase detection reaction/universal DNA array, and our EndoV/DNA ligase-based technologies for high-throughput detection of cancer-associated expression changes, mutations, deletions, insertions, gene amplification, LOH events, and methylation changes in colon cancers. (ii) Discover and characterize new cancer-pathways genes in invasive adenocarcinomas and metastases based on integrated analysis of expression and mutational profiles. (iii) Identify the patterns of molecular alterations that accumulate in the p53, cell cycle, apoptosis, Wnt signaling, RPTK signaling, and TGF Beta signaling pathway genes in individual tumors. (iv) Describe the progressive and sequential alterations in global gene expression and in the expression of specific cancer pathway genes during the evolution of colon neoplasia from atypical crypt focus to metastasis. (v) Develop a molecular classification of colon carcinogenesis, based upon genetic, epigenetic and mRNA expression profiling, and employ this taxonomy in predicting outcome or response to particular modes of therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA065930-06
Application #
6652144
Study Section
Subcommittee G - Education (NCI)
Program Officer
Couch, Jennifer A
Project Start
1997-03-01
Project End
2006-06-30
Budget Start
2003-07-01
Budget End
2004-06-30
Support Year
6
Fiscal Year
2003
Total Cost
$2,908,154
Indirect Cost
Name
Weill Medical College of Cornell University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
060217502
City
New York
State
NY
Country
United States
Zip Code
10065
Khan, Sajid A; Zeng, Zhaoshi; Shia, Jinru et al. (2017) EGFR Gene Amplification and KRAS Mutation Predict Response to Combination Targeted Therapy in Metastatic Colorectal Cancer. Pathol Oncol Res 23:673-677
Khan, Sajid A; Morris, Melinda; Idrees, Kamran et al. (2016) Colorectal cancer in the very young: a comparative study of tumor markers, pathology and survival in early onset and adult onset patients. J Pediatr Surg 51:1812-1817
Cheng, Yu-Wei; Pincas, Hanna; Huang, Jianmin et al. (2014) High incidence of LRAT promoter hypermethylation in colorectal cancer correlates with tumor stage. Med Oncol 31:254
Dharmasiri, Udara; Njoroge, Samuel K; Witek, Ma?gorzata A et al. (2011) High-throughput selection, enumeration, electrokinetic manipulation, and molecular profiling of low-abundance circulating tumor cells using a microfluidic system. Anal Chem 83:2301-9
Bacolod, Manny D; Barany, Francis (2011) Molecular profiling of colon tumors: the search for clinically relevant biomarkers of progression, prognosis, therapeutics, and predisposition. Ann Surg Oncol 18:3694-700
Nash, Garrett M; Gimbel, Mark; Cohen, Alfred M et al. (2010) KRAS mutation and microsatellite instability: two genetic markers of early tumor development that influence the prognosis of colorectal cancer. Ann Surg Oncol 17:416-24
Bacolod, Manny D; Barany, Francis (2010) Gene dysregulations driven by somatic copy number aberrations-biological and clinical implications in colon tumors: a paper from the 2009 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn 12:552-61
Cheng, Yu-Wei; Idrees, Kamran; Shattock, Richard et al. (2010) Loss of imprinting and marked gene elevation are 2 forms of aberrant IGF2 expression in colorectal cancer. Int J Cancer 127:568-77
Pingle, Maneesh; Rundell, Mark; Das, Sanchita et al. (2010) PCR/LDR/universal array platforms for the diagnosis of infectious disease. Methods Mol Biol 632:141-57
Nash, Garrett M; Gimbel, Mark; Shia, Jinru et al. (2010) KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Ann Surg Oncol 17:572-8

Showing the most recent 10 out of 74 publications